Investopedia: A New Accuray Starts To Emerge

Small-cap radiation oncology company Accuray (ARAY) has been struggling for a while now. Despite compelling technology that is superior to that of much larger rivals Varian (VAR) and Elekta (EKTAY) in at least some significant respects, Accuray's operational missteps have sent the stock down almost 20% over the past year and almost 45% over the past five years, making it a significant underperformer.

With that underperformance making the shareholders restless, a change in management followed and Josh Levine took the helm. It's really too soon to expect a big impact from Levine's new direction and strategic priorities, and the early results have been mixed. Even so, a big sequential rebound in orders gives investors reason for optimism and the stock opportunity is quite compelling if the company can perform up to the level of its technology.

Please read the full article here:
A New Accuray Starts To Emerge